- Previous Close
0.2700 - Open
0.2740 - Bid 0.1985 x 200
- Ask 0.3465 x 100
- Day's Range
0.2633 - 0.3080 - 52 Week Range
0.2530 - 3.6700 - Volume
106,685 - Avg. Volume
205,683 - Market Cap (intraday)
10.971M - Beta (5Y Monthly) 3.01
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5200 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.55
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
www.athira.comRecent News: ATHA
View MorePerformance Overview: ATHA
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATHA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATHA
View MoreValuation Measures
Market Cap
10.97M
Enterprise Value
-39.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.24
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-55.23%
Return on Equity (ttm)
-110.77%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-96.94M
Diluted EPS (ttm)
-2.5200
Balance Sheet and Cash Flow
Total Cash (mrq)
51.27M
Total Debt/Equity (mrq)
2.71%
Levered Free Cash Flow (ttm)
-60.51M